Across TCGA pan-cancer cohorts, CPT1B RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CPT1B data layer compared with 3 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CPT1B RNA is associated with better overall survival. In most high-consensus cancer types, elevated CPT1B expression acts as an unfavorable survival marker, although some lineages such as BLCA and HNSC show a favorable association.

BLCA, HNSC, and KIRC are the cancer types where CPT1B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.528	0.308	<.001	140	view →
HNSC	DFS	Median	II,III,IV	0.443	0.236	<.001	122	view →
KIRC	DFS	Tertile	All	0.500	0.721	<.001	90	view →
COAD	OS	Tertile	All	0.805	0.918	<.001	88	view →
ACC	DFS	Median	All	0.411	0.747	<.001	78	view →
MESO	DFS	Median	II,III,IV	0.208	0.692	.001	42	view →
SKCM	DFS	Quartile	III,IV	0.504	0.148	<.001	40	view →
LIHC	DFS	Tertile	II,III,IV	0.240	0.532	<.001	32	view →
PRAD	DFS	Median	All	0.676	0.897	<.001	28	view →
PAAD	DFS	Quartile	All	0.438	0.199	.004	23	view →
LAML	DFS	Quartile	All	0.362	0.705	.013	22	view →
STAD	DFS	Median	III,IV	0.367	0.601	.003	21	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

Exploration

Same gene, other analysis: CPT1B tumor-vs-normal RNA expression · all CPT1B data types